Probi AB's revenue for the
three
months ended in Sep. 2024 was kr143.7 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was kr630.4 Mil.
Probi AB's Revenue per Share for the
three
months ended in Sep. 2024 was kr12.61.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was kr55.33.
Warning Sign:
Probi AB revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Probi AB was 2.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -4.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 16.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Probi AB's highest 3-Year average Revenue per Share Growth Rate was 64.70% per year. The lowest was -11.90% per year. And the median was 13.00% per year.
Probi AB Revenue Historical Data
The historical data trend for Probi AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Probi AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probi AB's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Probi AB's Revenue distribution charts can be found below:
* The bar in red indicates where Probi AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr630.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probi AB (OSTO:PROB) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Probi AB Revenue Related Terms
Thank you for viewing the detailed overview of Probi AB's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. Its research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:PROB has been successfully added to your 